Form 4: James Healy Acquires 22,000 Stock Options in Bolt Biotherapeutics

Director James Healy acquired 22,000 stock options in Bolt Biotherapeutics on June 12, 2024, at an exercise price of $0.7682.

Summary

• On June 12, 2024, James Healy, a director of Bolt Biotherapeutics, Inc., acquired 22,000 stock options.
• The exercise price of these options is $0.7682.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
• The options will fully vest upon a change in control of the Issuer.
• The expiration date for the options is June 11, 2034.
• Following the transaction, Healy directly owns 22,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition, neither particularly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule and change in control provision suggest a long-term incentive structure for the director.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common in the biopharmaceutical industry, where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to align the interests of their leadership with those of shareholders.
• The vesting schedule and change in control provisions are typical features of these grants, designed to incentivize long-term performance and retention.

Stakeholder Impact

• The acquisition of stock options by a director can have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates